Literature DB >> 15897309

Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein.

L Senolt1, M Braun, M Olejárová, S Forejtová, J Gatterová, K Pavelka.   

Abstract

BACKGROUND: Pentosidine, an advanced glycation end product, increasingly accumulates in articular cartilage with age, and contributes to the pathogenesis of osteoarthritis (OA). Increased pentosidine concentrations are associated with inflammatory disorders-for example, rheumatoid arthritis.
OBJECTIVE: To compare pentosidine serum concentrations in patients with knee OA and in healthy volunteers and to determine a relationship between pentosidine and cartilage oligomeric matrix protein (COMP)-a marker of articular cartilage destruction.
METHODS: Paired serum and synovial fluid samples were obtained by arthrocentesis from 38 patients with knee OA and from 38 healthy volunteers. Pentosidine concentration was measured by reverse phase high performance liquid chromatography with fluorescent detection and COMP was determined by sandwich ELISA.
RESULTS: Significantly increased serum pentosidine (p<0.01) and COMP (p<0.05) levels were detected in the patients with OA compared with the control group. Serum pentosidine correlated significantly with synovial fluid pentosidine (p<0.001). Pentosidine in synovial fluid (p<0.05) and in serum (p<0.05) correlated significantly with synovial fluid COMP. Pentosidine and COMP concentrations did not correlate significantly with the radiological stage of the disease.
CONCLUSION: Increased pentosidine serum concentration in patients with OA and its correlation with the cartilage destruction marker COMP in synovial fluid suggests that pentosidine may be important in OA pathology and is a new potential OA marker.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897309      PMCID: PMC1755507          DOI: 10.1136/ard.2004.029140

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

1.  Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products.

Authors:  J DeGroot; N Verzijl; M J Wenting-Van Wijk; R A Bank; F P Lafeber; J W Bijlsma; J M TeKoppele
Journal:  Arthritis Rheum       Date:  2001-11

2.  Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis.

Authors:  J R Chen; M Takahashi; M Suzuki; K Kushida; S Miyamoto; T Inoue
Journal:  Rheumatology (Oxford)       Date:  1999-12       Impact factor: 7.580

Review 3.  Aging and the etiopathogenesis and treatment of osteoarthritis.

Authors:  R F Loeser
Journal:  Rheum Dis Clin North Am       Date:  2000-08       Impact factor: 2.670

4.  Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation.

Authors:  J DeGroot; N Verzijl; R A Bank; F P Lafeber; J W Bijlsma; J M TeKoppele
Journal:  Arthritis Rheum       Date:  1999-05

5.  A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee.

Authors:  K Pavelká; J Gatterová; V Gollerova; Z Urbanová; M Sedlácková; R D Altman
Journal:  Osteoarthritis Cartilage       Date:  2000-09       Impact factor: 6.576

6.  Age-related accumulation of Maillard reaction products in human articular cartilage collagen.

Authors:  N Verzijl; J DeGroot; E Oldehinkel; R A Bank; S R Thorpe; J W Baynes; M T Bayliss; J W Bijlsma; F P Lafeber; J M Tekoppele
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

7.  Degradation of the cartilage collagen matrix associated with changes in chondrocytes in osteoarthrosis. Assessment by loss of background fluorescence and immunodetection of matrix components.

Authors:  G J Gibson; J J Verner; F R Nelson; D L Lin
Journal:  J Orthop Res       Date:  2001-01       Impact factor: 3.494

8.  Analysis of cartilage oligomeric matrix protein (COMP) in synovial fibroblasts and synovial fluids.

Authors:  K M Hummel; M Neidhart; V Vilim; N Hauser; W K Aicher; R E Gay; S Gay; H J Häuselmann
Journal:  Br J Rheumatol       Date:  1998-07

9.  Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.

Authors:  S Sugiyama; T Miyata; Y Ueda; H Tanaka; K Maeda; S Kawashima; C Van Ypersele de Strihou; K Kurokawa
Journal:  J Am Soc Nephrol       Date:  1998-09       Impact factor: 10.121

10.  Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis.

Authors:  J R Chen; M Takahashi; M Suzuki; K Kushida; S Miyamoto; T Inoue
Journal:  J Rheumatol       Date:  1998-12       Impact factor: 4.666

View more
  20 in total

Review 1.  Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis.

Authors:  J M Hoch; C G Mattacola; J M Medina McKeon; J S Howard; C Lattermann
Journal:  Osteoarthritis Cartilage       Date:  2011-10-05       Impact factor: 6.576

2.  Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation.

Authors:  Shelby Addison; R Edward Coleman; Sheng Feng; Gary McDaniel; Virginia Byers Kraus
Journal:  Arthritis Rheum       Date:  2009-11

Review 3.  Chondropenia: current concept review.

Authors:  A Speziali; M Delcogliano; M Tei; G Placella; M Chillemi; R Tiribuzi; G Cerulli
Journal:  Musculoskelet Surg       Date:  2015-06-13

Review 4.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

5.  Methodology and applications of disease biomarker identification in human serum.

Authors:  Ziad J Sahab; Suzan M Semaan; Qing-Xiang Amy Sang
Journal:  Biomark Insights       Date:  2007-02-14

6.  Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study.

Authors:  H-C Chen; S Shah; T V Stabler; Y-J Li; V B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2008-03-04       Impact factor: 6.576

Review 7.  Use of biochemical markers to study and follow patients with osteoarthritis.

Authors:  Patrick Garnero
Journal:  Curr Rheumatol Rep       Date:  2006-02       Impact factor: 4.592

8.  Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods.

Authors:  Tomoko Matsumoto; Toshiyuki Tsurumoto; Hideo Baba; Makoto Osaki; Hiroshi Enomoto; Akihiko Yonekura; Hiroyuki Shindo; Toshio Miyata
Journal:  Rheumatol Int       Date:  2007-07-25       Impact factor: 2.631

9.  An exploratory study to investigate the association between age, physical activity, femoral trochlear cartilage thickness and biomarkers of tissue metabolism in adult males.

Authors:  Harry M Roberts; Claire L Griffith-McGeever; Julian A Owen; Lewis Angell; Jonathan P Moore; Jeanette M Thom
Journal:  Eur J Appl Physiol       Date:  2021-03-13       Impact factor: 3.078

Review 10.  Developments in the scientific understanding of osteoarthritis.

Authors:  Steven B Abramson; Mukundan Attur
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.